Pharmacoeconomics of atrial fibrillation and stroke prevention

Area of Science:

• Cardiology
• Pharmacology
• Health Economics

Background:

• Atrial fibrillation (AF) is a prevalent arrhythmia associated with a significant stroke risk due to left atrial appendage thrombi.
• Antithrombotic therapies, including aspirin and warfarin, effectively mitigate this stroke risk.
• Adjusted-dose warfarin offers superior stroke risk reduction compared to aspirin or low-dose warfarin, particularly in high-risk AF patients.

Purpose of the Study:

• To evaluate the cost-effectiveness of adjusted-dose warfarin in atrial fibrillation patients.
• To highlight the importance of maintaining therapeutic international normalized ratios (INRs) for optimal outcomes.

Main Methods:

• Review of existing literature on antithrombotic therapies for atrial fibrillation.
• Analysis of cost-effectiveness data for warfarin in different patient subgroups.
• Examination of the impact of international normalized ratio (INR) control on stroke and bleeding risks and associated costs.

Main Results:

• Adjusted-dose warfarin is cost-effective, especially for AF patients with additional risk factors.
• Maintaining INRs within the target range (2.0-3.0) minimizes both stroke and bleeding risks and associated healthcare expenditures.
• Subtherapeutic INRs are common and lead to increased stroke risk and higher costs.

Conclusions:

• Optimizing anticoagulation management in atrial fibrillation is essential for cost containment.
• Achieving and maintaining target international normalized ratios (INRs) with warfarin is a key strategy for reducing stroke incidence and healthcare costs.
• Effective anticoagulation monitoring and management can improve patient outcomes and reduce the economic burden of stroke in AF patients.